The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to ...

The agency will consider a submission that includes pooled data from ongoing studies, a decision analysts viewed as a notable ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...